Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review.

Eektimmerman F, Swen JJ, Madhar MB, Allaart CF, Guchelaar HJ.

Pharmacogenomics J. 2019 Oct 17. doi: 10.1038/s41397-019-0098-9. [Epub ahead of print] Review.

PMID:
31624331
2.

No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis.

Hissink Muller PCE, van Braak WG, Schreurs D, Nusman CM, Bergstra SA, Hemke R, Schonenberg-Meinema D, van den Berg JM, Kuijpers TW, Koopman-Keemink Y, van Rossum MAJ, van Suijlekom-Smit LWA, Brinkman DMC, Allaart CF, Ten Cate R, Maas M.

Pediatr Rheumatol Online J. 2019 Sep 4;17(1):62. doi: 10.1186/s12969-019-0362-1.

3.

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry.

Bergstra SA, Couto MC, Govind N, Chopra A, Salomon Escoto K, Murphy E, Huizinga TW, Allaart CF.

RMD Open. 2019 Jul 30;5(2):e000969. doi: 10.1136/rmdopen-2019-000969. eCollection 2019.

4.
5.

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Collée G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2019 Jan 18;21(1):28. doi: 10.1186/s13075-019-1815-0.

6.

Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.

Eektimmerman F, Allaart CF, Hazes JM, den Broeder AA, Fransen J, Swen JJ, Guchelaar HJ.

Pharmacogenomics. 2019 Jan;20(2):85-93. doi: 10.2217/pgs-2018-0144. Epub 2019 Jan 10.

PMID:
30628539
7.

Response to: 'Catching the falling star: points to consider when using propensity scores' by Ouyang et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Dec 30. pii: annrheumdis-2018-214892. doi: 10.1136/annrheumdis-2018-214892. [Epub ahead of print] No abstract available.

PMID:
30598466
8.

Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?

Hissink Muller PCE, Yildiz B, Allaart CF, Brinkman DMC, van Rossum M, van Suijlekom-Smit LWA, van den Berg JM, Ten Cate R, de Vries MC.

BMC Med Ethics. 2018 Dec 20;19(1):96. doi: 10.1186/s12910-018-0336-8.

9.

Response to: 'Metering the METEOR in methotrexate failure: is propensity score a falling star?' by Ahmed et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Nov 14. pii: annrheumdis-2018-214652. doi: 10.1136/annrheumdis-2018-214652. [Epub ahead of print] No abstract available.

PMID:
30429121
10.

How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies.

Bergstra SA, Winchow LL, Murphy E, Chopra A, Salomon-Escoto K, Fonseca JE, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2019 Jan;78(1):25-30. doi: 10.1136/annrheumdis-2018-213731. Epub 2018 Oct 16.

PMID:
30327328
11.

Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.

Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, Bekkering PW, Kuijpers TW, Van Rossum M, van Suijlekom-Smit LWA, van den Berg JM, Boehringer S, Allaart CF, Ten Cate R.

Ann Rheum Dis. 2019 Jan;78(1):51-59. doi: 10.1136/annrheumdis-2018-213902. Epub 2018 Oct 11.

PMID:
30309970
12.

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Goekoop-Ruiterman YPM, Steup-Beekman GM, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Ann Rheum Dis. 2018 Dec;77(12):1836-1838. doi: 10.1136/annrheumdis-2018-213823. Epub 2018 Jul 25. No abstract available.

PMID:
30045852
13.

Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.

Bergstra SA, Branco JC, Vega-Morales D, Salomon-Escoto K, Govind N, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Oct;77(10):1413-1420. doi: 10.1136/annrheumdis-2018-213289. Epub 2018 Jul 6.

PMID:
29980576
14.

Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.

Bergstra SA, Allaart CF, Ramiro S, Chopra A, Govind N, Silva C, Murphy EA, Landewé RBM.

J Rheumatol. 2018 Oct;45(10):1361-1366. doi: 10.3899/jrheum.171176. Epub 2018 Jun 15.

PMID:
29907672
15.

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis.

Akdemir G, Markusse IM, Bergstra SA, Goekoop RJ, Molenaar ET, van Groenendael JHLM, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF.

RMD Open. 2018 May 20;4(1):e000649. doi: 10.1136/rmdopen-2018-000649. eCollection 2018.

16.

SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients.

Eektimmerman F, Swen JJ, Böhringer S, Aslibekyan S, Allaart CF, Guchelaar HJ.

Pharmacogenomics. 2018 May;19(7):613-619. doi: 10.2217/pgs-2018-0021. Epub 2018 Apr 27.

PMID:
29701127
17.

Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.

de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, Speyer I, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2018 Feb 26;20(1):33. doi: 10.1186/s13075-018-1520-4.

18.

TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years.

Loef M, Kroon FPB, Bergstra SA, van der Pol JA, Lems WF, Kerstens PJSM, Allaart CF, Kloppenburg M.

Rheumatology (Oxford). 2018 Nov 1;57(11):1917-1924. doi: 10.1093/rheumatology/key016.

PMID:
29471377
19.

What is the optimal target for treat-to-target strategies in rheumatoid arthritis?

Bergstra SA, Allaart CF.

Curr Opin Rheumatol. 2018 May;30(3):282-287. doi: 10.1097/BOR.0000000000000484.

PMID:
29356697
20.

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.

Bergstra SA, Allaart CF, van den Berg R, Chopra A, Govind N, Huizinga TWJ, Landewe RBM.

Arthritis Res Ther. 2017 Nov 22;19(1):258. doi: 10.1186/s13075-017-1468-9.

21.

Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.

Akdemir G, Heimans L, Bergstra SA, Goekoop RJ, van Oosterhout M, van Groenendael JHLM, Peeters AJ, Steup-Beekman GM, Lard LR, de Sonnaville PBJ, Grillet BAM, Huizinga TWJ, Allaart CF.

Ann Rheum Dis. 2018 Jan;77(1):111-118. doi: 10.1136/annrheumdis-2017-211375. Epub 2017 Sep 28.

PMID:
28970207
22.

Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.

Bergstra SA, Olivas O, Akdemir G, Riyazi N, Collée G, van Groenendael JHLM, Landewé RBM, Allaart CF.

Arthritis Res Ther. 2017 Sep 30;19(1):220. doi: 10.1186/s13075-017-1425-7.

23.

Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.

Bergstra SA, Landewé RBM, Huizinga TWJ, Allaart CF.

Rheumatology (Oxford). 2017 Oct 1;56(10):1721-1728. doi: 10.1093/rheumatology/kex236.

PMID:
28957556
24.

What have we learned from BeSt?

Allaart CF, Markusse IM, Lems WF.

Clin Immunol. 2018 Jan;186:74-78. doi: 10.1016/j.clim.2017.09.017. Epub 2017 Sep 18.

25.

Time-averaged disease activity fits better joint destruction in rheumatoid arthritis.

Tsuji H, Yano K, Furu M, Yamakawa N, Ikari K, Hashimoto M, Ito H, Fujii T, Yamamoto W, Ohmura K, Taniguchi A, Momohara S, Matsuda F, Allaart CF, Yamanaka H, Mimori T, Terao C.

Sci Rep. 2017 Jul 19;7(1):5856. doi: 10.1038/s41598-017-05581-w.

26.

Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis.

Eektimmerman F, Swen JJ, Böhringer S, Huizinga TW, Kooloos WM, Allaart CF, Guchelaar HJ.

Pharmacogenomics. 2017 Jul;18(10):945-953. doi: 10.2217/pgs-2017-0047. Epub 2017 Jun 22.

PMID:
28639493
27.

Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example.

Burgers LE, Allaart CF, Huizinga TWJ, van der Helm-van Mil AHM.

Arthritis Rheumatol. 2017 May;69(5):926-931. doi: 10.1002/art.40062. Epub 2017 Mar 31.

28.

A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.

Hissink Muller PC, Brinkman DM, Schonenberg D, Koopman-Keemink Y, Brederije IC, Bekkering WP, Kuijpers TW, van Rossum MA, van Suijlekom-Smit LW, van den Berg JM, Allaart CF, Ten Cate R.

Pediatr Rheumatol Online J. 2017 Feb 6;15(1):11. doi: 10.1186/s12969-017-0138-4.

29.

Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement.

Cohen D, Rijnink EC, Nabuurs RJ, Steup-Beekman GM, Versluis MJ, Emmer BJ, Zandbergen M, van Buchem MA, Allaart CF, Wolterbeek R, Bruijn JA, van Duinen SG, Huizinga TW, Bajema IM.

Rheumatology (Oxford). 2017 Jan;56(1):77-86. doi: 10.1093/rheumatology/kew341. Epub 2016 Oct 25.

PMID:
28028157
30.

Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.

Bergstra SA, Allaart CF, Stijnen T, Landewé RBM.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1473-1483. doi: 10.1002/acr.23164. Epub 2017 Aug 31. Review.

31.

Age affects joint space narrowing in patients with early active rheumatoid arthritis.

Matthijssen XM, Akdemir G, Markusse IM, Stijnen T, Riyazi N, Han KH, Bijkerk C, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

RMD Open. 2016 Oct 18;2(2):e000338. eCollection 2016.

32.

Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.

Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VSK, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C; Members of the Rheumatoid Arthritis Challenge Consortium, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TWJ, Kurreeman F, Allaart CF, Bridges SL Jr, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM.

Nat Commun. 2016 Oct 10;7:13205. doi: 10.1038/ncomms13205. No abstract available.

33.

Rheumatologists' adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission.

Akdemir G, Markusse IM, Goekoop-Ruiterman YP, Steup-Beekman GM, Grillet BA, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Clin Rheumatol. 2017 Feb;36(2):317-326. doi: 10.1007/s10067-016-3405-8. Epub 2016 Sep 28.

34.

Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.

Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VSK, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C; Members of the Rheumatoid Arthritis Challenge Consortium, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TWJ, Kurreeman F, Allaart CF, Louis Bridges S Jr, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM.

Nat Commun. 2016 Aug 23;7:12460. doi: 10.1038/ncomms12460. Erratum in: Nat Commun. 2016 Oct 10;7:13205.

35.

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG.

Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.

PMID:
27287832
36.

When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS).

Gvozdenović E, Allaart CF, van der Heijde D, Ferraccioli G, Smolen JS, Huizinga TW, Landewé R.

RMD Open. 2016 Apr 28;2(1):e000221. doi: 10.1136/rmdopen-2015-000221. eCollection 2016.

37.

Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial.

Akdemir G, Markusse IM, Dirven L, Riyazi N, Steup-Beekman GM, Kerstens P, Lems WF, Huizinga T, Allaart CF.

RMD Open. 2016 Mar 25;2(1):e000143. doi: 10.1136/rmdopen-2015-000143. eCollection 2016.

38.

Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.

Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, Molenaar TH, Le Cessie S, Lems WF, van der Lubbe PA, Kerstens PJ, Peeters AJ, Ronday HK, de Sonnaville PB, Speyer I, Stijnen T, Ten Wolde S, Huizinga TW, Allaart CF.

Ann Intern Med. 2016 Apr 19;164(8):523-31. doi: 10.7326/M15-0919. Epub 2016 Mar 1.

PMID:
27089068
39.

Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study.

Akdemir G, Verheul MK, Heimans L, Wevers-de Boer KV, Goekoop-Ruiterman YP, van Oosterhout M, Harbers JB, Bijkerk C, Steup-Beekman GM, Lard LR, Huizinga TW, Trouw LA, Allaart CF.

RMD Open. 2016 Feb 15;2(1):e000172. doi: 10.1136/rmdopen-2015-000172. eCollection 2016.

40.

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.

Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2016 Aug;68(8):1810-7. doi: 10.1002/art.39626.

41.

Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).

Heimans L, Akdemir G, Boer KV, Goekoop-Ruiterman YP, Molenaar ET, van Groenendael JH, Peeters AJ, Steup-Beekman GM, Lard LR, de Sonnaville PB, Grillet BA, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2016 Jan 21;18:23. doi: 10.1186/s13075-015-0912-y.

42.

Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritis.

Bergstra SA, Markusse IM, Akdemir G, Ronday HK, Han KH, Lems WF, Kerstens PJSM, van den Berg R, Landewé RBM, Allaart CF.

Clin Rheumatol. 2016 Aug;35(8):2101-2107. doi: 10.1007/s10067-015-3145-1. Epub 2015 Dec 22.

43.

An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.

van Heemst J, Trouw LA, Nogueira L, van Steenbergen HW, van der Helm-van Mil AH, Allaart CF, Serre G, Holmdahl R, Huizinga TW, Toes RE, van der Woude D.

Arthritis Res Ther. 2015 Oct 5;17:276. doi: 10.1186/s13075-015-0786-z.

44.

Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database.

Gvozdenović E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landewé RB.

J Clin Rheumatol. 2015 Oct;21(7):349-54. doi: 10.1097/RHU.0000000000000296.

PMID:
26398461
45.

Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.

Markusse IM, Dirven L, Gerards AH, van Groenendael JH, Ronday HK, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2015 Aug 31;17:232. doi: 10.1186/s13075-015-0730-2.

46.

Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis.

Terao C, Yamakawa N, Yano K, Markusse IM, Ikari K, Yoshida S, Furu M, Hashimoto M, Ito H, Fujii T, Ohmura K, Murakami K, Takahashi M, Hamaguchi M, Tabara Y, Taniguchi A, Momohara S, Raychaudhuri S, Allaart CF, Yamanaka H, Mimori T, Matsuda F.

Arthritis Rheumatol. 2015 Dec;67(12):3113-23. doi: 10.1002/art.39306.

47.

Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation.

Markusse IM, Dirven L, Han KH, Ronday HK, de Sonnaville PB, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Care Res (Hoboken). 2016 Apr;68(4):446-53. doi: 10.1002/acr.22681.

48.

Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'--authors' reply.

Markusse IM, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2015 Jul 2;17:171. doi: 10.1186/s13075-015-0681-7. No abstract available.

49.

Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment.

Wevers-de Boer KV, Heimans L, Visser K, Schouffoer AA, Molenaar ET, van Groenendael JH, Peeters AJ, Speyer I, Collée G, Huizinga TW, Allaart CF.

Rheumatology (Oxford). 2015 Aug;54(8):1380-4. doi: 10.1093/rheumatology/keu477. Epub 2015 Feb 15.

PMID:
25687553
50.

Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best?

Markusse IM, Dirven L, Han KH, Ronday HK, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Care Res (Hoboken). 2015 May;67(6):739-45. doi: 10.1002/acr.22540.

Supplemental Content

Loading ...
Support Center